Oncology drug approvals: Evaluating endpoints and evidence in an era of breakthrough therapies

Oncologist

Volumn 22, Issue 7, 2017, Pages 762-767

  Blumenthal, Gideon M ^a   Kluetz, Paul G ^a   Schneider, Julie ^a   Goldberg, Kirsten B ^a   McKee, Amy E ^a   Pazdur, Richard ^a,b  

^a Center for Drug Evaluation and Research   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ANTI CD38; ANTI SLAMF7; AVELUMAB; CABOZANTINIB; CORTICOSTEROID; CRIZOTINIB; CYTARABINE; DACARBAZINE; DASATINIB; DENOSUMAB; DINUTUXIMAB; ERLOTINIB; EVEROLIMUS; IMATINIB; INTERLEUKIN 2; NILOTINIB; OSIMERTINIB; PROTEASOME INHIBITOR; RITUXIMAB; RUXOLITINIB; SILTUXIMAB; SONIDEGIB; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VISMODEGIB;

ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DESIGN; FOOD AND DRUG ADMINISTRATION; GENE REARRANGEMENT; HUMAN; MELANOMA; MULTIPLE MYELOMA; MYELOFIBROSIS; NON SMALL CELL LUNG CANCER; ONCOLOGY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; TUMOR GROWTH; PROCEDURES;

DRUG APPROVAL; HUMANS; MEDICAL ONCOLOGY;

EID: 85024114589     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2017-0152     Document Type: Article

References (49)

1. Sherman RE, Li J, Shapley S et al. Expediting drug development—The FDA’s new “breakthrough therapy” designation. N Engl J Med 2013;369:1877-1880.
2. Shea M, Ostermann L, Hohman R et al. Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development. Nat Rev Drug Discov 2016;15:152.
3. Pazdur R. Endpoints for assessing drug activity in clinical trials. The Oncologist 2008;13:19-21.
4. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med 2015;373:1541-1552.
5. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann InternMed 1977;87:293-298.
6. Hanna NH, Einhorn LH. Testicular cancer—Discoveries and updates. N Engl J Med 2014;371:2005-2016.
7. Cohen MH, Moses ML, Pazdur R. Gleevac for the treatment of chronic myelogenous leukemia: U.S. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. The Oncologist 2002;7:390-392.
8. O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl JMed 2003;348:994-1004.
9. Hochhaus A, Larson RA, Guilhot F et al. Longterm outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917-927.
10. Malik SM, Maher VE, Bijwaard KE et al. U.S. Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014;20:2029-2034.
11. Kazandjian D, Blumenthal GM, Chen HY et al. FDA approval summary: Crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. The Oncologist 2014;19:e5-e11.
12. U.S. Food and Drug Administration. FDA Briefing Document, Oncologic Drugs Advisory Committee Meeting April 12, 2011, NDA 22334 AfinitorVR (everolimus), Applicant: Novartis Pharmaceuticals. Available at https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm250378.pdf. Accessed March 30, 2017.
13. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee Meeting, Morning Session, March 20, 2012. Available at https://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/OncologicDrugsAdvisory-Committee/UCM304478.pdf. Accessed March 30, 2017.
14. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee Meeting, Morning Session, December 7, 2011. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM288716.pdf. Accessed March 30, 2017.
15. U.S. Food and Drug Administration. Meeting of the Oncologic Drugs Advisory Committee, Morning Session, July 14, 2011. Available at https://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/OncologicDrugsAdvisory-Committee/UCM268656.pdf. Accessed March 30, 2017.
16. U.S. Food and Drug Administration. Meeting of the Oncologic Drugs Advisory Committee, Afternoon Session, July 14, 2011. Available at https://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/OncologicDrugsAdvisory-Committee/UCM268657.pdf. Accessed March 30, 2017.
17. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee, April 12, 2011, Morning Session. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM256370.pdf. AccessedMarch 30, 2017.
18. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee, April 12, 2011, Afternoon Session. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM256372.pdf. AccessedMarch 30, 2017.
19. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee, December 2, 2010. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM237499.pdf. Accessed March 30, 2017.
20. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee, Morning Session, October 5, 2009. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM191020.pdf. AccessedMarch 30, 2017.
21. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee, Afternoon Session, October 5, 2009. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM191021.pdf. AccessedMarch 30, 2017.
22. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee Discussion of New Drug Application (NDA) 022-393, Proposed Trade Name Istodax (romidepsin) Injection for treatment of cutaneous T-Cell lymphoma (CTCL), Gloucester Pharmaceuticals, Inc. September 2, 2009. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM183276.pdf. Accessed March 30, 2017.
23. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee Discussion of New Drug Application (NDA) 022-468, Proposed Trade Name Folotyn (pralatrexate) Injection for treatment of patients with relapsed or refractory (recurring and/or not responsive to other treatments) peripheral Tcell lymphoma (PTCL), Allos Therapeutics, Inc. September 2, 2009. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM183277.pdf. AccessedMarch 30, 2017.
24. U.S. Food and Drug Administration. Summary Minutes of the Oncologic Drugs Advisory Committee May 29, 2009. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM170152.pdf. AccessedMarch 30, 2017.
25. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee, Avastin (bevacizumab) for the Treatment of Previously Treated Glioblastoma Multiforme. March 31, 2009. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM148933.pdf. Accessed March 30, 2017.
26. Blumenthal GM, Pazdur R. Response rate as an approval end point in oncology: Back to the future. JAMA Oncol 2016;2:780-781.
27. Kurzrock R, Stewart DJ. Equipoise abandoned? Randomization and clinical trials. Ann Oncol 2013; 24:2471-2474.
28. Simon R, Blumenthal GM, Rothenberg ML et al. The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther 2015; 97:502-507.
29. Blumenthal GM, Karuri SW, Zhang H et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 2015;33:1008-1014.
30. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl JMed 2013;368:2385-2394.
31. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334.
32. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
33. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Available at https://seer.cancer.gov/faststats. Accessed April 5, 2017.
34. Deisseroth A, Kaminskas E, Grillo J et al. U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 2012;18: 3212-3217.
35. Kluetz PG, Slagle A, Papadopoulos EJ et al. Focusing on patient-reported outcomes in cancer clinical trials: Symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res 2016;22:1553-1558.
36. Bower H, Bjorkholm M, Dickman PW et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016;34:2851-2857.
37. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
38. Drawid A, Kaura S, Kiely D et al. Impact of novel therapies on multiple myeloma survival in the US: Current and future outcomes. J Clin Oncol 2015 [Epub ahead of print].
39. Jawad I, Wilkerson J, Prasad V et al. Colorectal survival gains and novel treatment regimens: A systemic review and analysis. JAMA Oncol 2015;1: 787-795.
40. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27: 3677-3683.
41. Lowes, R. Avastin no longer approved for breast cancer, FDA says. Medscape, November 18, 2011. Available at http://www.medscape.com/viewarticle/753862. AccessedMay 12, 2017.
42. AstraZeneca Pharmaceuticals LP; Withdrawal of Approval of a New Drug Application for Iressa. Federal Register, April 25, 2012. Available at https://www.federalregister.gov/documents/2012/04/25/2012-9944/astrazeneca-pharmaceuticals-lp-withdrawal-of-approval-of-a-new-drug-application-foriressa. Accessed May 12, 2017.
43. Nelson, R. Gemtuzumab voluntarily withdrawn from US Market.Medscape, June 21, 2010. Available at http://www.medscape.com/viewarticle/723957. AccessedMay 12, 2017.
44. Khozin S, Blumenthal GM, Jiang X et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. The Oncologist 2014;19: 774-779.
45. Kazandjian D, Blumenthal GM, Yuan W et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res 2016;22: 1307-1312.
46. Stenger, M. Modified Indication for Erlotinib in Advanced Non-Small Cell Lung Cancer. ASCO Post, November 10, 2016. Available at http://www.ascopost.com/issues/november-10-2016/modified-indication-for-erlotinib-in-advanced-non-small-cell-lungcancer/. Accessed May 12, 2017.
47. Chabner BA. Approval after phase 1: Ceritinib runs the three-minute mile. The Oncologist 2014;19: 577-578.
48. Prowell TM, Theoret MR, Pazdur R. Seamless oncology-drug development. N Engl J Med 2016; 374:2001-2003.
49. Sherman, RE, Anderson SA, Dal Pan GJ et al. Real-world evidence—What is it and what can it tell us? N Engl JMed 2016;375:2293-2297.